Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 5/20 | 0.47 |
| ▸ | BCHE | P06276 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4767726 | 0.88 | CNR2 (0.57) | CNR2KDM4EALDH1A1ACHEBCHE | |
| SCHEMBL19147985 | 0.86 | CNR2 (0.63) | CNR2KDM4EALDH1A1ACHEBCHE | |
| SCHEMBL30471915 | 0.86 | ALDH1A1 (0.50) | CNR2KDM4EUSP2ALDH1A1ACHE | |
| SCHEMBL11556471 | 0.82 | ALDH1A1 (0.52) | CNR2KDM4EALDH1A1ACHEBCHE | |
| SCHEMBL14003142 | 0.80 | KDM4E (0.45) | CNR2KDM4EUSP2ALDH1A1POLB | |
| SCHEMBL11507398 | 0.79 | CNR2 (0.43) | CNR2KDM4EALDH1A1ACHEBCHE | |
| SCHEMBL4767957 | 0.79 | ALDH1A1 (0.52) | CNR2KDM4EALDH1A1ACHEBCHE | |
| SCHEMBL4768929 | 0.78 | POLB (0.59) | CNR2KDM4EALDH1A1ACHEBCHE | |
| SCHEMBL8175634 | 0.78 | ADRA2A (0.50) | CNR2KDM4EALDH1A1ACHEBCHE | |
| SCHEMBL10501065 | 0.78 | ADORA2A (0.39) | KDM4EUSP2PDE4AADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349848-B2 | Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors | Dogwoof Pharmaceuticals, Inc. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349848-B2 | Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors | Dogwoof Pharmaceuticals, Inc. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349848-B2 | Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors | Dogwoof Pharmaceuticals, Inc. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20090082347-A1 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC | 2009-03-26 | — | — | US | disclosed |
| US-20090082347-A1 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC | 2009-03-26 | — | — | US | disclosed |
| US-20090082347-A1 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC | 2009-03-26 | — | — | US | disclosed |
| EP-1678181-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS INC (US) | 2008-12-31 | — | — | EP | disclosed |
| US-7470697-B2 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors | ADENOSINE THERAPEUTICS, LLC (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470697-B2 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors | ADENOSINE THERAPEUTICS, LLC (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470697-B2 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors | ADENOSINE THERAPEUTICS, LLC (US) | 2008-12-30 | — | — | US | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449473-B2 | Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080125425-A1 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2badenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2008-05-29 | — | — | US | disclosed |
| US-20080125425-A1 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2badenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2008-05-29 | — | — | US | disclosed |
| US-20080125425-A1 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2badenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2008-05-29 | — | — | US | disclosed |
| WO-2008027585-A2 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008027585-A2 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-06 | — | — | WO | disclosed |
| EP-1678181-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20050119287-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005042534-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125425-A1 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2badenosine receptors | ADORA2B, ADORA2A, ADORA3 | CNR2 67/4885KDM4E 2977/4885USP2 4367/4885 |
| US-20050119287-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA3 | CNR2 21/4885KDM4E 3386/4885USP2 1300/4885 |
| US-20090082347-A1 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADORA2B, ADORA2A, ADORA3 | CNR2 61/4885KDM4E 3826/4885USP2 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.